There are plenty of ways that we use technology in psychiatric practice these days—including e-prescribing, electronic health records, referring patients to websites for psychoeducation, etc. But when was the last time you referred a patient to their computer for psychotherapy? Well, it may be time to consider it.
Read More
Get advice on how you can become a top-performing clinician, including how to put processes in place to consistently get feedback from your patients, in an interview with Scott D. Miller, PhD, found and director of the International Center for Clinical Excellence.
Read More
Repetitive transcranial magnetic stimulation (rTMS) is approved by the US Food and Drug Administration (FDA) for treatment resistant depression (TRD), and presumably works by modulating brain circuitry. A new meta-analysis focuses specifically on using rTMS as augmentation to antidepressants in patients with TRD.
Read More
Lisdexamfetamine (Vyvanse), a stimulant approved for treating kids and adults with ADHD, is the first drug approved by the US Food and Drug Administration (FDA) for treating adults with binge-eating disorder (BED).
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
